Clinical significance of HIV-associated bone loss

When and how to intervene

Michael T. Yin, Elizabeth Shane, Kathryn Anastos

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Moderate decreases in bone mineral density (BMD) occur after initiation of several antiretroviral regimens. However, BMD appears to Stabilize over time. Alendronate and zoledronate therapy decreases bone turnover markers and increases BMD in HIV-positive subjects with low BMD. Low BMD is a common problem, but whether this translates into increased incidence or prevalence of fragility fractures is uncertain. Screening and treatment of osteoporosis in HIV-positive individuals should follow guidelines for the general population. When there is a strong indication to treat, bisphosphonates should be considered as first-line therapy as studies have demonstrated their short-term efficacy for increasing BMD and their tolerability in HIV-infected individuals. In this article, we review recent publications on bone loss, fractures and treatment of osteoporosis in HIV-positive individuals.

Original languageEnglish (US)
Pages (from-to)465-478
Number of pages14
JournalFuture HIV Therapy
Volume2
Issue number5
DOIs
StatePublished - 2008

Fingerprint

Bone Density
HIV
Bone and Bones
zoledronic acid
Osteoporosis
Alendronate
Bone Remodeling
Bone Fractures
Diphosphonates
Guidelines
Incidence
Therapeutics
Population

Keywords

  • Bisphosphonates
  • Bone density
  • Bone loss
  • Fracture
  • HIV
  • Osteoporosis treatment

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

Clinical significance of HIV-associated bone loss : When and how to intervene. / Yin, Michael T.; Shane, Elizabeth; Anastos, Kathryn.

In: Future HIV Therapy, Vol. 2, No. 5, 2008, p. 465-478.

Research output: Contribution to journalArticle

Yin, Michael T. ; Shane, Elizabeth ; Anastos, Kathryn. / Clinical significance of HIV-associated bone loss : When and how to intervene. In: Future HIV Therapy. 2008 ; Vol. 2, No. 5. pp. 465-478.
@article{2f0f937e4e114c21a7b9aebc272fa939,
title = "Clinical significance of HIV-associated bone loss: When and how to intervene",
abstract = "Moderate decreases in bone mineral density (BMD) occur after initiation of several antiretroviral regimens. However, BMD appears to Stabilize over time. Alendronate and zoledronate therapy decreases bone turnover markers and increases BMD in HIV-positive subjects with low BMD. Low BMD is a common problem, but whether this translates into increased incidence or prevalence of fragility fractures is uncertain. Screening and treatment of osteoporosis in HIV-positive individuals should follow guidelines for the general population. When there is a strong indication to treat, bisphosphonates should be considered as first-line therapy as studies have demonstrated their short-term efficacy for increasing BMD and their tolerability in HIV-infected individuals. In this article, we review recent publications on bone loss, fractures and treatment of osteoporosis in HIV-positive individuals.",
keywords = "Bisphosphonates, Bone density, Bone loss, Fracture, HIV, Osteoporosis treatment",
author = "Yin, {Michael T.} and Elizabeth Shane and Kathryn Anastos",
year = "2008",
doi = "10.2217/17469600.2.5.465",
language = "English (US)",
volume = "2",
pages = "465--478",
journal = "Future HIV Therapy",
issn = "1746-9600",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Clinical significance of HIV-associated bone loss

T2 - When and how to intervene

AU - Yin, Michael T.

AU - Shane, Elizabeth

AU - Anastos, Kathryn

PY - 2008

Y1 - 2008

N2 - Moderate decreases in bone mineral density (BMD) occur after initiation of several antiretroviral regimens. However, BMD appears to Stabilize over time. Alendronate and zoledronate therapy decreases bone turnover markers and increases BMD in HIV-positive subjects with low BMD. Low BMD is a common problem, but whether this translates into increased incidence or prevalence of fragility fractures is uncertain. Screening and treatment of osteoporosis in HIV-positive individuals should follow guidelines for the general population. When there is a strong indication to treat, bisphosphonates should be considered as first-line therapy as studies have demonstrated their short-term efficacy for increasing BMD and their tolerability in HIV-infected individuals. In this article, we review recent publications on bone loss, fractures and treatment of osteoporosis in HIV-positive individuals.

AB - Moderate decreases in bone mineral density (BMD) occur after initiation of several antiretroviral regimens. However, BMD appears to Stabilize over time. Alendronate and zoledronate therapy decreases bone turnover markers and increases BMD in HIV-positive subjects with low BMD. Low BMD is a common problem, but whether this translates into increased incidence or prevalence of fragility fractures is uncertain. Screening and treatment of osteoporosis in HIV-positive individuals should follow guidelines for the general population. When there is a strong indication to treat, bisphosphonates should be considered as first-line therapy as studies have demonstrated their short-term efficacy for increasing BMD and their tolerability in HIV-infected individuals. In this article, we review recent publications on bone loss, fractures and treatment of osteoporosis in HIV-positive individuals.

KW - Bisphosphonates

KW - Bone density

KW - Bone loss

KW - Fracture

KW - HIV

KW - Osteoporosis treatment

UR - http://www.scopus.com/inward/record.url?scp=55349100506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349100506&partnerID=8YFLogxK

U2 - 10.2217/17469600.2.5.465

DO - 10.2217/17469600.2.5.465

M3 - Article

VL - 2

SP - 465

EP - 478

JO - Future HIV Therapy

JF - Future HIV Therapy

SN - 1746-9600

IS - 5

ER -